Dynavax Technologies, developer of biopharmaceuticals used to prevent and treat Hepatitis B and C, has brought in $20.1 million of a targeted $38.9 million round of equity, debt, securities, options, warrants and rights, according to a filing with the SEC. Based in Berkeley, Calif., the company trades on the Nasdaq under the symbol DVAX.